Histidine

Histidine

SCHEMBL4589353

CNCC(=O)[O-].CNCC(=O)[O-].N[C@@H](Cc1c[nH]cn1)C(=O)O.N[C@@H](Cc1c[nH]cn1)C(=O)O.[Mn+2]

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.37
CYP3A4 P08684 1/20 0.37
CYP1A2 P05177 2/20 0.36
GRIA2 P42262 8/20 0.35
GRIA1 P42261 7/20 0.35
GRIA3 P42263 7/20 0.35
GRIA4 P48058 7/20 0.35
GRIK1 P39086 4/20 0.34
GRIK5 Q16478 4/20 0.34
GRIK2 Q13002 3/20 0.34
GRIK3 Q13003 3/20 0.34
GRIK4 Q16099 3/20 0.34
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL2813584 0.97 SLC7A5 (0.37) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL5598694 0.90 SLC7A5 (0.38) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL28335300 0.85 SLC7A5 (0.41) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL27759487 0.85 SLC7A5 (0.43) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL3050307 0.85 SLC7A5 (0.49) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL28093403 0.85 SLC7A5 (0.45) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL3050310 0.85 SLC7A5 (0.49) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL8080341 0.85 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL3258 0.85 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2GRIA2GRIA1
Histidine SCHEMBL163443 0.85 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2GRIA2GRIA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 US disclosed
EP-1765280-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HYPERPIGMENTATION OF SKIN PROCYTE CORPORATION (US) 2007-03-28 EP disclosed
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2006-11-02 US disclosed
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin PROCYTE CORPORATION (US) 2006-01-26 US disclosed
WO-2006004787-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HYPERPIGMENTATION OF SKIN PROCYTE CORPORATION (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin RBP1, RBP4, SOD1 SLC7A5 1876/4885CYP3A4 4549/4885CYP1A2 3205/4885
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin RBP1, RBP4, MC1R SLC7A5 1015/4885CYP3A4 4639/4885CYP1A2 3145/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 SLC7A5 1876/4885CYP3A4 4549/4885CYP1A2 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.